LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Consensus Rating of “Moderate Buy” by Analysts

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $94.57.

LMAT has been the topic of a number of recent research reports. Oppenheimer reissued an “outperform” rating and issued a $93.00 target price (up previously from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Barrington Research raised their target price on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research note on Friday, November 1st. Finally, Cantor Fitzgerald started coverage on shares of LeMaitre Vascular in a research note on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price target on the stock.

Insider Activity

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of the stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the completion of the transaction, the director now directly owns 2,278 shares of the company’s stock, valued at approximately $231,148.66. This trade represents a 62.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 10.79% of the company’s stock.

Institutional Investors Weigh In On LeMaitre Vascular

Institutional investors and hedge funds have recently modified their holdings of the company. Pacer Advisors Inc. boosted its position in LeMaitre Vascular by 8.4% during the fourth quarter. Pacer Advisors Inc. now owns 2,950 shares of the medical instruments supplier’s stock worth $272,000 after purchasing an additional 228 shares in the last quarter. KBC Group NV raised its stake in shares of LeMaitre Vascular by 58.4% during the 4th quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier’s stock worth $102,000 after buying an additional 410 shares during the last quarter. Linden Thomas Advisory Services LLC grew its stake in LeMaitre Vascular by 5.6% in the 4th quarter. Linden Thomas Advisory Services LLC now owns 34,482 shares of the medical instruments supplier’s stock valued at $3,177,000 after acquiring an additional 1,834 shares during the last quarter. SG Americas Securities LLC acquired a new stake in LeMaitre Vascular in the 4th quarter valued at about $158,000. Finally, Albion Financial Group UT raised its position in LeMaitre Vascular by 5.7% during the fourth quarter. Albion Financial Group UT now owns 3,796 shares of the medical instruments supplier’s stock worth $350,000 after acquiring an additional 204 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Price Performance

Shares of NASDAQ:LMAT opened at $96.31 on Friday. LeMaitre Vascular has a 1-year low of $56.04 and a 1-year high of $109.58. The stock has a market cap of $2.17 billion, a P/E ratio of 52.63, a P/E/G ratio of 2.19 and a beta of 0.96. The firm has a fifty day moving average price of $98.18 and a 200 day moving average price of $92.23.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.05. The business had revenue of $54.82 million during the quarter, compared to the consensus estimate of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business’s quarterly revenue was up 15.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.33 earnings per share. Sell-side analysts expect that LeMaitre Vascular will post 1.94 EPS for the current fiscal year.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.